The risk of cardiovascular disease or death was about the same for Type 2 diabetics who took either GlaxoSmithKline's Avandia or Takeda Pharmaceutical's Actos, according to a study funded by health insurer WellPoint. The finding contradicts several studies indicating that Avandia appears to be riskier than Actos.

Related Summaries